Evaluation of an adjuvanted hydrogel-based pDNA nanoparticulate vaccine for rabies prevention and immunocontraception
- PMID: 31279062
- PMCID: PMC11287484
- DOI: 10.1016/j.nano.2019.102049
Evaluation of an adjuvanted hydrogel-based pDNA nanoparticulate vaccine for rabies prevention and immunocontraception
Abstract
Immunocontraceptive vaccination is becoming an acceptable strategy in managing animal populations. Mass vaccination of dogs is the most cost-effective and efficient method to control rabies, and combination of rabies vaccination and animal population control will be an added advantage. In this study, we developed an adjuvanted hydrogel-based pDNA nanoparticulate vaccine for rabies protection and immunocontraception. In vivo, we observed an immune response skewed toward a Th2 type, in contrast to the Th1 type in our previous pDNA study. The observation was verified by the IgG2a/IgG1 ratio (<1), and cytokine expression profile of IL-4 and IFN-γ. The humoral immune response is key for rabies protection and a GnRH antibody-based immunocontraception. In mice, anti-GnRH antibody titers were detected 4 weeks after immunization and lasted for 12 weeks, post animal experiment was terminated. The adjuvanted pDNA nanoparticulate vaccine shows promise for future studies evaluating protection from rabies challenge and prevention of animal breeding.
Keywords: Gonadotrophin-releasing hormone (GnRH); Immunocontraceptive vaccine; Poloxamer gels; Rabies.
Copyright © 2019 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure
The authors report no conflicts of interest in this work. The authors alone are responsible for the content and writing of this article.
Figures










Similar articles
-
Laser-assisted skin delivery of immunocontraceptive rabies nanoparticulate vaccine in poloxamer gel.Eur J Pharm Sci. 2020 Dec 1;155:105560. doi: 10.1016/j.ejps.2020.105560. Epub 2020 Sep 17. Eur J Pharm Sci. 2020. PMID: 32949750 Free PMC article.
-
No adverse effects of simultaneous vaccination with the immunocontraceptive GonaCon and a commercial rabies vaccine on rabies virus neutralizing antibody production in dogs.Vaccine. 2009 Nov 27;27(51):7210-3. doi: 10.1016/j.vaccine.2009.09.026. Vaccine. 2009. PMID: 19925955
-
Ginsenoside Re as an adjuvant to enhance the immune response to the inactivated rabies virus vaccine in mice.Int Immunopharmacol. 2014 Jun;20(2):283-9. doi: 10.1016/j.intimp.2014.03.008. Epub 2014 Mar 25. Int Immunopharmacol. 2014. PMID: 24680943
-
Deviation of the allergic IgE to an IgG response by gene immunotherapy.Int Rev Immunol. 1999;18(3):271-89. doi: 10.3109/08830189909043030. Int Rev Immunol. 1999. PMID: 10614729 Review.
-
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.Semin Immunol. 2018 Oct;39:14-21. doi: 10.1016/j.smim.2018.05.001. Epub 2018 May 23. Semin Immunol. 2018. PMID: 29801750 Review.
Cited by
-
Microneedle Delivery of an Adjuvanted Microparticulate Vaccine Induces High Antibody Levels in Mice Vaccinated against Coronavirus.Vaccines (Basel). 2022 Sep 7;10(9):1491. doi: 10.3390/vaccines10091491. Vaccines (Basel). 2022. PMID: 36146568 Free PMC article.
-
Reproductive and Behavioral Evaluation of a New Immunocastration Dog Vaccine.Animals (Basel). 2020 Jan 31;10(2):226. doi: 10.3390/ani10020226. Animals (Basel). 2020. PMID: 32023851 Free PMC article.
-
Hydrogels in Contraceptive Applications and Their Mechanisms of Action.ACS Appl Bio Mater. 2025 Jun 16;8(6):4580-4591. doi: 10.1021/acsabm.5c00556. Epub 2025 Jun 3. ACS Appl Bio Mater. 2025. PMID: 40462481 Free PMC article. Review.
-
Laser-assisted skin delivery of immunocontraceptive rabies nanoparticulate vaccine in poloxamer gel.Eur J Pharm Sci. 2020 Dec 1;155:105560. doi: 10.1016/j.ejps.2020.105560. Epub 2020 Sep 17. Eur J Pharm Sci. 2020. PMID: 32949750 Free PMC article.
-
New Prospects in Neutering Male Animals Using Magnetic Nanoparticle Hyperthermia.Pharmaceutics. 2021 Sep 14;13(9):1465. doi: 10.3390/pharmaceutics13091465. Pharmaceutics. 2021. PMID: 34575541 Free PMC article.
References
-
- Bose A, Munshi R, Tripathy RM, Madhusudana SN, Harish BR, Thaker S, Mahendra BJ, Gunale B, Gogtay NJ, Thatte UM, Mani RS, Manjunath K, George K, Yajaman AB, Sahai A, Dhere RM, Alex RG, Adhikari DD, Abhilash null, Raghava V, Kumbhar D, Behera TR, Kulkarni PS, A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes, Vaccine. 34 (2016) 4820–4826. doi: 10.1016/j.vaccine.2016.08.005. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical